Technetium Tc99m etarfolatide

Drug Profile

Technetium Tc99m etarfolatide

Alternative Names: 99mTC-Etarfolatide; EC 145 companion diagnostic - Endocyte; EC-20; Etarfolatide; Etarfolatide TC99m; Folate-Tc99m; FolateScan; FOLCEPRI; In 111-EC20; NMK 20; Tc 99m-EC20; Vintafolide companion diagnostic

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Nihon Medi-Physics
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Pituitary cancer; Renal cell carcinoma
  • Phase I Solid tumours
  • Preregistration Submission Withdrawal Ovarian cancer
  • Discontinued Inflammation

Most Recent Events

  • 28 Aug 2015 Development of technetium etarfolatide is still ongoing for Pituitary cancer and Renal cell carcinoma (Diagnosis) in USA (Endocyte pipeline, August 2015)
  • 31 Mar 2015 Technetium Tc99m etarfolatide is still in phase II trials for Non-small cell lung cancer (Diagnosis) in USA and Europe
  • 31 Mar 2015 Discontinued - Phase-II for Inflammation (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top